AGIO - Company ID 0001439222
The table below shows AGIOS PHARMACEUTICALS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$118.92M | -$111.49M | -$99.87M | -$95.18M | -$97.73M | -$120.75M |
| Capital expenditure | $769.00K | $766.00K | $141.00K | $399.00K | $2.80M | $1.01M |
| Investing cash flow | $141.31M | $112.59M | $124.56M | $57.60M | -$26.57M | $1.87B |
| Dividends paid | - | - | - | - |
AGIOS PHARMACEUTICALS, INC. reported operating cash flow of -$372.98M for fiscal year 2025. That is up 4.3% from -$389.84M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $38.56M (FY 2016) to -$372.98M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $2.08M | $1.62M | $5.86M | $2.47M | $1.21M | $7.26M |